Table 4

Difference in Medicare spending in the last 30 days of life by primary outpatient oncologist type

ParameterModel 1: SimpleModel 2: Multivariable*
NSpending ($)95% CIP valueSpending ($)95% CIP value
Short stay, long stay, and skilled nursing facilities
Medical oncologist770546 38843 592 to 49 1850.52844 20341 734 to 46 6720.010
Gynecologic oncologist448448 40042 816 to 53 98352 15447 053 to 57 255
Physician/suppliers†(Medicare Part B)
Medical oncologist770526482551 to 2744<0.00126432560 to 2727<0.001
Gynecologic oncologist448423432202 to 248323502235 to 2466
Institutional outpatient providers
Medical oncologist770593988727 to 10 0690.41694278771 to 10 0830.482
Gynecologic oncologist448499068882 to 10 93098568892 to 10 821
Hospice
Medical oncologist770515 74314 981 to 16 5040.03516 02415 306 to 16 7430.158
Gynecologic oncologist448417 62216 050 to 19 19417 13815 836 to 18 439
Home health agency
Medical oncologist770512771194 to 13600.00512621180 to 13450.023
Gynecologic oncologist44841082974 to 119011071007 to 1207
Durable medical equipment
Medical oncologist7705194164 to 2240.827177149 to 2040.116
Gynecologic oncologist4484188148 to 229218174 to 262
Part D
Medical oncologist77051128974 to 12830.2381112960 to 12640.475
Gynecologic oncologist44841007879 to 11361035901 to 1169
  • *Covariates included in the multivariable regression models: age at death, race, ethnicity, marital status, median income of residential zip code at death, percent of people with less than a high school education in the residential zip code at death, SEER registry at death, residential urban status at death, year of diagnosis, year of death, cancer site, cause of death, stage at diagnosis, Medicare/Medicaid dual eligibility at death, and CCI at death.

  • †Suppliers includes non-physician providers including advanced practice providers, social workers, some laboratories, emergency medical services providers, and some ambulatory surgical centers.

  • CCI, Charlson Ccomorbidity Iindex ; CI, confidence interval; SEER, Surveillance, Epidemiology and End Results .